Home — Sponsor HK

A reported IPO timetable should be treated as an operational milestone, not as a substitute for official exchange information. For licensed sponsors, issuer teams and compliance functions, the key control is to connect each public date and transaction term with the relevant disclosure and supporting due-diligence record.

What the public report says

The reported timetable and offering terms are:

Scheduled offer period: 7–12 October.
Expected listing date: 15 October.
Allocation: 10% to the Hong Kong public offering and the remainder to the international offering.
Offer price: HK$35.3–38.8 per share.
Board lot: 100 shares, with a reported entry fee of HK$3,919.13.
Cornerstone investors: 11 investors.
Sole sponsor: CITIC Securities.

The date qualifier is important. HKEX’s Newly Listed Securities page states that an asterisk identifies a tentative listing or trading date. Accordingly, 15 October should continue to be described as the expected or tentative date unless and until confirmed through official HKEX information.

Checks for issuers and sponsors

Sponsor teams should check that the reported offer-opening, offer-closing and expected listing dates are accurately and consistently reflected across the relevant disclosure materials.
Distinguish reported, expected, tentative and confirmed dates. The Guandian report uses expected listing language, while HKEX identifies an asterisk as tentative. Those status labels should not be used interchangeably in internal approvals, board materials, investor communications or public-facing statements.
Recheck the core offering terms alongside the timetable. Any timetable review should also reconcile the proposed share count, public and international allocations, offer-price range, lot size, entry fee, maximum fundraising figure and cornerstone subscriptions reported by Guandian. The aim is not to substitute new figures, but to ensure that changes are reflected consistently wherever those figures appear.
Apply professional scepticism to timetable-related disclosure. The supplied HKEX Practice Note PN2 excerpt says sponsors should make the inquiries necessary to become reasonably satisfied with disclosure in the listing document. It requires a critical assessment and alertness to information—including information from experts—that contradicts or questions the reliability of statements, representations or other information. A timetable change should therefore be treated as a potential diligence event, not merely a diary update.
Review expert information used in the listing narrative. The report attributes Transsion’s global handset-market position to Frost & Sullivan: by 2025 revenue, the company ranked eighth globally with a 1.7% market share. Under the professional-scepticism standard described in PN2, expert information should be examined for consistency and for indications that may question its reliability. Attribution alone should not close the inquiry.
Address restricted information expressly. The HKEX guidance excerpt states that where a sponsor is denied access to certain information by law, the sponsor must demonstrate the steps taken to fulfil its due-diligence obligations. It also refers to independent due diligence and possible disclosure. Any reliance on alternative work should therefore be recorded and assessed against the disclosure implications described in the guidance.
Confirm the sponsor role and independence analysis. Guandian identifies CITIC Securities as sole sponsor. The supplied A&O Shearman overview notes that an issuer may appoint one sponsor or more than one joint sponsor, and that at least one sponsor must be independent of the issuer under the applicable tests. The sponsor file should record the appointment and independence assessment; the supplied Guandian excerpt does not itself state the conclusion of that assessment.
Use indicative timelines for planning purposes. A&O describes its Hong Kong IPO timetable as indicative and says it covers both Hong Kong and non-Hong Kong issuers. It should therefore support planning and challenge questions, but it does not establish Transsion-specific dates or replace transaction-specific disclosure.

Practical responsibility split

Issuer teams should notify sponsors and compliance functions promptly of proposed timetable or offering-term changes and identify the evidence supporting each change.
Sponsor teams should connect the revised disclosure to their reasonable-inquiry work, record contradictory information considered and assess whether further disclosure is required.
Internal compliance and sponsor-relations teams should maintain the distinction between a media-reported date, an expected date, an HKEX tentative date and a confirmed listing date. External communications should use the same status terminology.

Bottom line

The supplied public report places Transsion’s expected Hong Kong listing on 15 October, following a scheduled 7–12 October offer period. That date is operationally useful but remains subject to confirmation. For sponsors and compliance teams, the central question is not only whether the timetable is current, but whether the timetable, related offering terms, expert claims and sponsor disclosures remain fully supported by a documented and professionally sceptical due-diligence process.

Guandian itself notes that its content and data were compiled from public information, do not constitute investment advice and should be verified before use.